Degron Therapeutics
PrivateLast Round
Series A
Extension
May 14, 2026
Total Funding Raised
$132M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Degron Therapeutics is a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets using its proprietary molecular glue-based targeted protein degradation drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Degron Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Degron Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 14, 2026 | ||||
| Strategic | May 23, 2024 | ||||
| Series A | Jun 9, 2022 | ||||
| Seed | Apr 1, 2021 |
Key People
Founding team and executive leadership
Degron Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series A |
| Fengchuan Capital | Series A |
| Longmen Capital | Series A |
| Co-Win Ventures | Series A, Seed |
| YuanBio Venture Capital | Series A, Seed |
| Baidu Ventures | Series A |
| GF Xinde Investment Management | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 14, 2026
$40M round led by Lapam Capital.
- May 14, 2024
$40M round led by Lapam Capital.
Degron Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Degron Therapeutics's valuation, stock price, and market status.